The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma. The major dose-limiting toxicity was granulocytopenia. There was one toxic death from sepsis. Central nervous system and renal toxicity occurred infrequently, perhaps as a result of the continuous-infusion schedule. This regimen is being evaluated further in advanced disease, the adjuvant setting, and in combination with bone marrow colony-stimulating factors.
|Original language||English (US)|
|Number of pages||9|
|Journal||Seminars in oncology|
|Issue number||2 SUPPL. 4|
|State||Published - Apr 1990|
All Science Journal Classification (ASJC) codes